Long-term prediction of prostate cancer: Prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population

Journal of Clinical Oncology

Volumn 26, Issue 6, 2008, Pages 835-841

  Ulmert, David ^a   Serio, Angel M ^a   O'Brien, Matthew F ^a   Becker, Charlotte ^a   Eastham, James A ^a   Scardino, Peter T ^a   Björk, Thomas ^a   Berglund, Göran ^a   Vickers, Andrew J ^a   Lilja, Hans ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ACCURACY; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PRIORITY JOURNAL; PROSTATE CANCER; REGRESSION ANALYSIS; ADULT; AGED; BLOOD; COMPARATIVE STUDY; IMMUNOLOGY; INCIDENCE; METHODOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; SWEDEN; TIME;

ADULT; AGED; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RESEARCH DESIGN; SWEDEN; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 39749180009     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1490     Document Type: Article

References (33)

1. Farkas A, Schneider D, Perrotti M, et al: National trends in the epidemiology of prostate cancer, 1973 to 1994: Evidence for the effectiveness of prostate-specific antigen screening. Urology 52:444-448, 1998
2. Newcomer LM, Stanford JL, Blumenstein BA, et al: Temporal trends in rates of prostate cancer: Declining incidence of advanced stage disease, 1974 to 1994. J Urol 158:1427-1430, 1997
3. Stephenson RA, Stanford JL: Population-based prostate cancer trends in the United States: Patterns of change in the era of prostate-specific antigen. World J Urol 15:331-335, 1997
4. Ruckle HC, Klee GG, Oesterling JE: Prostate-specific antigen: Critical issues for the practicing physician. Mayo Clin Proc 69:59-68, 1994
5. Carter HB, Pearson JD, Metter EJ, et al: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220, 1992
6. Fang J, Metter EJ, Landis P, et al: PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml. Urology 59:889-893, 2002
7. Ito K, Yamamoto T, Ohi M, et al: Usefulness of prostate-specific antigen velocity in screening for prostate cancer. Int J Urol 9:316-321, 2002
8. Lynn NN, Collins GN, O'Reilly PH: The short-term prostate-specific antigen velocity before biopsy can be used to predict prostatic histology. BJU Int 85:847-850, 2000
9. Goluboff ET, Heitjan DF, DeVries GM, et al: Pretreatment prostate specific antigen doubling times: Use in patients before radical prostatectomy. J Urol 158:1876-1878, 1997
10. Hanks GE, Hanlon AL, Lee WR, et al: Pretreatment prostate-specific antigen doubling times: Clinical utility of this predictor of prostate cancer behavior. Int J Radiat Oncol Biol Phys 34:549-553, 1996
11. Lee WR, Hanks GE, Corn BW, et al: Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. Int J Radiat Oncol Biol Phys 31:21-24, 1995
12. Egawa S, Arai Y, Tobisu K, et al: Use of pretreatment prostate-specific antigen doubling time to predict outcome after radical prostatectomy. Prostate Cancer Prostatic Dis 3:269-274, 2000
13. D'Amico AV, Chen MH, Roehl KA, et al: Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med 351:125-135, 2004
14. D'Amico AV, Renshaw AA, Sussman B, et al: Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA 294:440-447, 2005
15. Carter HB, Ferrucci L, Kettermann A, et al: Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 98:1521-1527, 2006
16. Lilja H, Ulmert D, Björk T, et al: Long-term prediction of prostate cancer in a large, representative Swedish cohort: Prostate kallikreins measured at age 44-50 predict prostate cancer up to 25 years before diagnosis. J Clin Oncol 25:431-436, 2007
17. Berglund G, Eriksson KF, Israelsson B, et al: Cardiovascular risk groups and mortality in an urban Swedish male population: The Malmö Preventive Project. J Intern Med 239:489-497, 1996
18. Berglund G, Nilsson P, Eriksson KF, et al: Long-term outcome of the Malmö preventive project: Mortality and cardiovascular morbidity. J Intern Med 247:19-29, 2000
19. Ulmert D, Becker C, Nilsson JA, et al: Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. Clin Chem 52:235-239, 2006
20. Mitrunen K, Pettersson K, Piironen T, et al: Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 41:1115-1120, 1995
21. Rafferty B, Rigsby P, Rose M, et al: Reference reagents for prostate-specific antigen (PSA): Establishment of the first international standards for free PSA and PSA (90:10). Clin Chem 46:1291-1292, 2000
22. Vickers AJ, Elkin EB: Decision curve analysis: A novel method for evaluating prediction models. Med Decis Making 26:565-574, 2006
23. Thompson IM, Chi C, Ankerst DP, et al: Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 98:1128-1133, 2006
24. Carter HB, Pearson JD, Waclawiw Z, et al: Prostate-specific antigen variability in men without prostate cancer: Effect of sampling interval on prostate-specific antigen velocity. Urology 45:591-596, 1995
25. Riffenburgh RH, Amling CL: Use of early PSA velocity to predict eventual abnormal PSA values in men at risk for prostate cancer. Prostate Cancer Prostatic Dis 6:39-44, 2003
26. Roobol MJ, Kranje R, de Koning HJ, et al: Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam). Urology 63:309-313, 2004
27. Bruun L, Becher C, Hugosson J, et al: Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomised prostate cancer screening program in Sweden. Prostate 65:216-221, 2005
28. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 152:1743-1748, 1994
29. Vickers AJ, Ulmert D, Serio AM, et al: The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically-based screening strategy. Int J Cancer 121:2212-2217, 2007
30. Schröder FH, Roobol MJ, van der Kwast TH, et al: Does PSA velocity predict prostate cancer in pre-screened populations? Eur Urol 49:460-465, 2006
31. Thompson IM, Ankerst DP, Chi C, et al: Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98:529-534, 2006
32. Steuber T, Niemela P, Haese A, et al: Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 63:13-18, 2005
33. Haese A, Graefen M, Steuber T, et al: Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. J Urol 170:2269-2273, 2003